Trial
NCT01332279
Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Fox Chase Cancer Center
Collaborators
—
Condition
Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Intervention
everolimus
Why stopped
Pharmaceutical co. withdrew support. Study was never activated and did not accrue any patients.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-04-04